Dr. Ooi Kai Yun treats all cancer types with a special interest in breast, cervical, uterine, colorectal, lung, gastrointestinal and hepatobiliary cancers and advanced radiotherapy techniques.
After graduating with a Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Malaya, Malaysia, Dr. Ooi furthered her medical career by obtaining a Fellowship of the Royal College of Radiologists (FRCR) in Clinical Oncology and she served as a medical officer in the oncology department at Kuala Lumpur Hospital in Malaysia.
From 2019-2021, Dr. Ooi continued to specialise in Oncology as a clinical fellow during her tenure at two renowned institutions in the UK, The Christie NHS Trust and The Royal Marsden NHS Trust. With a keen interest in research, Dr. Ooi has participated in numerous clinical trials both as a principal investigator and co-investigator on breast, lung, head and neck, esophageal, urothelial and prostate cancers. She has co-authored oncology publications which includes ‘A retrospective audit into the prophylactic use of antibiotics in patients receiving chemotherapy for lung cancer’ during her fellowship at The Christie NHS Trust, UK. She was also the Lead in the Clinical and Translational Radiation Oncology Journal (2021) for ‘Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation’.
Exemplifying excellence in every endeavour, Dr. Ooi frequently received invitations to speak at global and regional conferences. Notably, she presented at the European Society for Medical Oncology (ESMO) preceptorship course, where she shared insights on Gastrointestinal Tumours and Metastatic Colorectal Cancer. Additionally, she contributed to the Best of ASCO 2022 conference in Malaysia, discussing topics related to metastatic or unresectable melanoma.
Since 2023, Dr. Ooi has been representing Malaysia for several international projects such as The Federation of Asian Organisations for Radiation Oncology for breast cancer and The International Atomic Energy Agency (IAEA) project on radiotherapy.
Dr. Ooi is committed to provide personalised and evidence-based treatments with care and compassion. She is able to converse in English, Mandarin, Bahasa Melayu, Cantonese and Hokkien.
International Representative for Malaysia
2023 – present : Breast working group, The Federation of Asian Organisations for Radiation Oncology. Current project : FERN-BR-001(WG:Breast/Health Economics), Burden of Financial toxicity in breast cancer patients treated with curative intent: a multinational study from low middle income countries
2023 – present : Lead country coordinator for The International Atomic Energy Agency (IAEA) project : RAS6110, “Improving the Radiotherapy Capacity of Newcomer Government Parties (RCA)”
Research
- Co-investigator IMpower132 Trial (2017) – stage IV non squamous non-small cell lung cancer
- Co-investigator of IMvigor130 (2017) – untreated locally advanced or metastatic urothelial carcinoma
- Co-investigator of KEYNOTE-975 (2018) – advanced / metastatic esophageal carcinoma
- Co-investigator of “Phase 3, open-label, randomised, non-inferiority International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer.” PACE-B (2020)
- Principal investigator AP063-003 (2024) – HER2+ Breast Cancer
- Principal investigator of eVOLVE-HNSCC (2024) – Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
- Principal investigator 20210033 (2024) – Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer